Trial Profile
A Phase II, Multi-center, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Novartis Pharma KK; Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 08 Dec 2021 New source identified and integrated Japan Pharmaceutical Information Center - Clinical Trials Information (JapicCTI142701)
- 06 Feb 2019 Status changed from recruiting to completed.
- 12 Jul 2018 Planned primary completion date changed from 30 Jan 2018 to 28 Feb 2019.